These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 12870431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D, Losert D, Wacheck V.
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
    Niu J, Xu Z, Li XN, Han Z.
    Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S.
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [Abstract] [Full Text] [Related]

  • 10. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS, Wengel J.
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [Abstract] [Full Text] [Related]

  • 11. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI, Cheng K, Guntaka RV.
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [Abstract] [Full Text] [Related]

  • 12. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH.
    Cancer Res; 2007 Apr 01; 67(7):2938-43. PubMed ID: 17409398
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. siRNA-based approaches in cancer therapy.
    Devi GR.
    Cancer Gene Ther; 2006 Sep 01; 13(9):819-29. PubMed ID: 16424918
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted delivery of small interfering RNA: approaching effective cancer therapies.
    Pirollo KF, Chang EH.
    Cancer Res; 2008 Mar 01; 68(5):1247-50. PubMed ID: 18316585
    [Abstract] [Full Text] [Related]

  • 17. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A, Vlassov AV.
    Med Sci Monit; 2006 Apr 01; 12(4):RA67-74. PubMed ID: 16572063
    [Abstract] [Full Text] [Related]

  • 18. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A.
    Curr Opin Mol Ther; 2007 Aug 01; 9(4):345-52. PubMed ID: 17694447
    [Abstract] [Full Text] [Related]

  • 19. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
    Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I.
    J Natl Cancer Inst; 2004 Aug 18; 96(16):1219-30. PubMed ID: 15316057
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery.
    Golzio M, Mazzolini L, Moller P, Rols MP, Teissié J.
    Gene Ther; 2005 Feb 18; 12(3):246-51. PubMed ID: 15592423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.